P2RY12 and atrial fibrillation: Since the clinical efficacy of DAPT as compared with OAC was established in RCTs in the late 1990s, DAPT, consisting of aspirin and a P2Y12 inhibitor, has been the cornerstone of antithrombotic management in patients undergoing PCI [3], while OAC with vitamin K antagonist (VKA) was superior to DAPT in reducing ischemic events among patients with AF [4].